Melanocortins in research: complete guide to Melanotan II, PT-141 bremelanotide, afamelanotide and MC1R-MC5R receptors

The melanocortin system is a central and peripheral neuroendocrine network formed by five G protein-coupled receptors (MC1R through MC5R), their endogenous ligands derived from proopiomelanocortin (POMC) — alpha-MSH, beta-MSH, gamma-MSH, ACTH — and their natural antagonists agouti (ASIP) and AgRP. This system simultaneously governs skin pigmentation, central energy homeostasis, sexual function, sebaceous exocytosis and the hormonal stress response. Synthetic melanocortin analogs used in research — Melanotan II (MT-II), PT-141 (bremelanotide), afamelanotide (Scenesse) — target this system with distinct selectivity profiles and constitute one of the most mature clusters of modern peptide pharmacology.

This guide consolidates all publicly available data through late 2025 on melanocortin biology, MC1R-MC5R distribution and signaling, molecular structures and mechanisms of the three reference analogs, selectivity comparisons, pharmacokinetics, reconstitution protocols for research, safety signals to monitor and regulatory outlook. All references are intended for research use only (RUO), in vitro and in vivo, in accordance with applicable requirements in France and Europe.

The melanocortin system: POMC and endogenous ligands

All endogenous melanocortin ligands derive from a single precursor, proopiomelanocortin (POMC), a 241-amino acid polypeptide encoded by the POMC gene on chromosome 2p23.3. POMC is primarily expressed in the anterior pituitary, the hypothalamic arcuate nucleus, skin melanocytes, keratinocytes and some brainstem neurons. Post-translational cleavage of POMC by the proconvertases PC1/3 and PC2 successively generates ACTH, endorphins and the three MSH forms (alpha-, beta-, gamma-).

Alpha-MSH (melanocyte-stimulating hormone) is a tridecapeptide of 13 amino acids (sequence SYSMEHFRWGKPV, N-terminal acetylated and C-terminal amidated) discovered in the 1950s. Its plasma half-life is on the order of 2 to 5 minutes, making direct therapeutic exploitation impractical. ACTH shares the 1-13 sequence of alpha-MSH and acts as both a melanocortin agonist and the main regulator of the adrenal cortex. Beta-MSH (18aa) and gamma-MSH (12aa) have more restricted tissue expression.

Melanocortin signaling is counterbalanced by two endogenous antagonists: agouti signaling protein (ASIP), which blocks MC1R and MC4R in melanocytes and adipose tissue, and agouti-related peptide (AgRP), which antagonizes MC3R and MC4R in the hypothalamus and modulates food intake.

MC1R-MC5R receptors: distribution and functions

The five melanocortin receptors belong to class A GPCRs and primarily couple Gs protein (adenylate cyclase activation and cyclic AMP increase). Each has a distinct tissue distribution and physiological function.

MC1R is primarily expressed on epidermal melanocytes, iris melanocytes and some immune cells. Its activation induces melanogenesis via the cAMP -> PKA -> CREB -> MITF pathway (microphthalmia-associated transcription factor), which activates tyrosinase-encoding genes and converts pheomelanin (red-yellow) into eumelanin (brown-black). Loss-of-function variants of MC1R underlie red hair and fair skin phenotypes.

MC2R is the ACTH receptor in the adrenal cortex. It is essential for glucocorticoid steroidogenesis. Its loss-of-function mutation causes familial glucocorticoid deficiency type 1.

MC3R is expressed in the central nervous system (hypothalamus, limbic system) and participates in energy homeostasis regulation, particularly through modulation of circadian food intake rhythm.

MC4R is the central target of food intake and body weight regulation. Expressed in the hypothalamic paraventricular nucleus, its activation suppresses appetite and increases energy expenditure. MC4R loss-of-function mutations constitute the most frequent monogenic cause of severe genetic obesity. MC4R is also implicated in central sexual function, via projections to the preoptic area and paraventricular ganglion, biological substrate of the pro-erectile and pro-libido effects of MC4R agonists.

MC5R is expressed in exocrine glands (sebaceous, lacrimal, harderian) and participates in sebum production and grooming in rodents.

Melanotan II (MT-II): structure and mechanism

Melanotan II is a synthetic cyclic heptapeptide with sequence Ac-Nle⁴-Asp⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Lys¹⁰-NH₂ with a lactam bridge between Asp⁵ and Lys¹⁰ that cyclizes the molecule and stabilizes the active conformation. Its molecular mass is 1024.2 Da, its CAS number 121062-08-6, and its molecular formula C₅₀H₆₉N₁₅O₉.

Developed in the 1980s by Victor Hruby's team at the University of Arizona as a potential photo-protector to prevent skin cancer, MT-II is a non-selective pan-agonist of all five melanocortin receptors MC1R to MC5R, with sub-nanomolar affinity. N-terminal acetylation, the Nle⁴ substitution (methionine replaced by norleucine, oxidation-resistant), the D-Phe⁷ substitution (stereochemical inversion resistant to proteolysis) and lactam cyclization are the four pharmacochemical innovations that transform alpha-MSH's 2-5 minute half-life into a multi-hour half-life.

MT-II signaling mainly passes through Gs / cAMP / PKA at each MC1R-MC5R receptor. Via MC1R, MT-II induces marked cutaneous hyperpigmentation (eumelanogenesis); via central MC4R, it suppresses food intake and stimulates sexual function; via MC5R, it increases sebum secretion.

Melanotan II pharmacokinetics

Administered subcutaneously in research, MT-II displays a plasma half-life of approximately 33 minutes to 1 hour across studies. Its subcutaneous bioavailability is high (> 80%). Clearance is essentially peptidic (non-specific enzymes). Pigmentation effects accumulate over days to weeks of repeated administration, because melanogenesis is a slow process dependent on melanocyte turnover (4-6 weeks for a complete epidermal cycle).

Central penetration is modest but sufficient to recruit hypothalamic MC4R receptors, which explains the anorexigenic and pro-sexual effects observed at above-pigmentary doses.

PT-141 (bremelanotide): structure and mechanism

PT-141, or bremelanotide, is a decyclized version of Melanotan II: same heptapeptide sequence Nle-Asp-His-D-Phe-Arg-Trp-Lys but with a free acid C-terminal end (no amidation) instead of the MT-II-closing lactam bridge. Its molecular mass is 1025.2 Da, its CAS number 189691-06-3, its molecular formula C₅₀H₆₈N₁₄O₁₀.

This apparently minor structural modification profoundly alters receptor selectivity: PT-141 shows a MC4R and MC3R preference over MC1R, which dissociates pro-sexual and central anorexigenic effects from cutaneous pigmentary effects. This dissociation enabled clinical development and 2019 FDA approval of bremelanotide under the name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.

The central mechanism rests on activation of MC4R neurons in the paraventricular nucleus projecting to the preoptic area and limbic structures involved in sexual motivation, triggering a pro-erectile response in men and pro-libido response in women. The action is independent of the vascular system (no effect on nitric oxide synthase) and distinct from the PDE5 mechanism of sildenafil-type inhibitors.

Afamelanotide (Scenesse): first approved MSH analog

Afamelanotide, formerly NDP-alpha-MSH (Nle⁴-D-Phe⁷-alpha-MSH), is a linear 13-amino acid analog of alpha-MSH bearing the same two key substitutions as MT-II (Nle⁴, D-Phe⁷). Its CAS number is 75921-69-6, its molecular mass 1646.9 Da. It retains the full length of alpha-MSH and is not cyclized, showing a predominantly MC1R selectivity profile.

Developed by the Australian company Clinuvel Pharmaceuticals under the commercial name Scenesse, afamelanotide received EMA approval in 2014 and FDA approval in 2019 for the prevention of phototoxicity in patients with erythropoietic protoporphyria (EPP), a rare orphan disease. Administered via a biodegradable subcutaneous implant releasing the peptide over approximately 60 days, it induces photoprotective eumelanogenesis.

Afamelanotide represents the historical first regulatory approval of a melanocortin analog for a pigmentation indication, clinically validating the peptide engineering strategy begun 30 years earlier.

MC1R / MC3R / MC4R / MC5R selectivity comparisons

The three molecules present distinctive selectivity profiles that govern their uses.

MT-II: pan-agonist MC1R-MC5R with sub-nanomolar affinity. Cumulative pigmentation + satiety + sexuality + sebum effects. Broadest effects profile but also hardest to dissociate clinically.

PT-141: MC3R/MC4R preference over MC1R. Preferential satiety + sexuality effects; attenuated (but not zero) pigmentary effects at high doses. Profile validating HSDD use without marked pigmentation.

Afamelanotide: MC1R preference. Preferential pigmentation effects; attenuated central effects at therapeutic doses. Profile validating EPP use with controlled pigmentation.

In vitro characterization is classically done on cloned human receptors expressed in cell lines (HEK293, CHO) via cAMP measurements (ELISA, FRET) or beta-arrestin recruitment (BRET, NanoBiT). Published K_i inhibition constants and EC₅₀ guide the design of new analogs.

Reconstitution protocols (research use only)

Lyophilized MT-II and PT-141 are typically reconstituted with bacteriostatic water (0.9% benzyl alcohol). For a 10 mg vial, standard reconstitution in 1 ml of bacteriostatic water gives a 10 mg/ml concentration. Volume flexibility allows adjusting concentration to 5 mg/ml (2 ml), 2.5 mg/ml (4 ml) or 1 mg/ml (10 ml, discouraged for labile peptides) depending on the experimental design.

Critical research parameters: reconstitution temperature (ideally 2-8 °C), slow injection against the vial wall to avoid shear denaturation, gentle swirling (no aggressive vortex), and complete homogenization before sampling. MT-II's lactam cyclization confers superior stability compared with linear PT-141 in aqueous solution.

Stability, storage and interferences

In lyophilized state, MT-II and PT-141 store for several years at -20 °C protected from light and moisture. After reconstitution, documented stability is 28 to 30 days at 2-8 °C under aseptic handling. Major degradation pathways to monitor are tryptophan oxidation (residue sensitive to UV light and oxidants), D-Phe⁷ epimerization in basic media, and hydrolysis of the MT-II lactam bond in prolonged acidic media.

Compatibility with common buffers (PBS, Tris, HEPES) is preserved at pH 5-8. Avoid ionic detergent solutions or thiols (DTT, beta-mercaptoethanol) that can perturb the active conformation.

Intracellular signaling and secondary pathways

MC1R-MC5R receptor activation primarily couples Gs but also recruits, to varying extents depending on the receptor and agonist, other pathways: Gq (phospholipase C, IP3, calcium), Gi under certain conditions (notably MC3R), and the ERK1/2 MAP kinase pathway via arrestin and EGFR transactivation. This signaling complexity constitutes the substrate of the functional bias observed between agonists.

At MC1R, the canonical Gs -> cAMP -> PKA -> CREB -> MITF pathway is the main melanogenesis lever. At MC4R, the hypothalamic Gs pathway combined with ERK1/2 pathways and modulation of ion channels (ATP-sensitive potassium channel Kir6.2) underpins satietogenic signaling.

Clinical safety and signals to monitor

The most frequent side effects under MT-II and PT-141 are nausea (dose-dependent, related to central MC4R activation), hot flashes, fatigue, and — for MT-II — marked hyperpigmentation of skin, pre-existing nevi and mucosae. MT-II is associated with reported cases of benign nevi modification (darkening) and, more rarely, with dermatological concerns (warranting dermato-oncological surveillance in at-risk subjects). PT-141 can induce priapic erection episodes in men (central penile MC4R activation), justifying dedicated monitoring.

Afamelanotide, via Scenesse, benefits from a well-characterized safety profile in EPP therapeutic use: controlled cutaneous hyperpigmentation, rare digestive effects, no major cardiovascular signal.

Heritage and perspectives

POMC and its derivatives have been discovered over nearly a century: alpha-MSH identification by Harris in the 1950s, POMC characterization by Nakanishi and Numa (Nature, 1979), cloning of the five MC1R-MC5R receptors between 1992 and 1994 (Cone, Mountjoy, Gantz teams). MT-II and PT-141 analogs from the Hruby program preceded clinical validation by afamelanotide (Scenesse) and bremelanotide (Vyleesi).

Current perspectives include: setmelanotide (Imcivree, Rhythm Pharmaceuticals, FDA-approved 2020), selective MC4R agonist for rare monogenic obesities (LEPR, POMC, PCSK1 deficit, Bardet-Biedl syndrome); biased MC1R agonists for targeted photo-protection; MC5R agonists for sebaceous pathologies; and MC3R/MC4R antagonists for cachexia and anorexia.

Conclusion

The melanocortin system is one of the most mature and most diversified clusters of modern peptide pharmacology. Five receptors, four endogenous ligands, three reference synthetic analogs (MT-II, PT-141, afamelanotide) and two regulatory approvals (Scenesse, Vyleesi) cover a spectrum ranging from pigmentation to sexual function, via energy homeostasis and sebaceous exocytosis. The increasing precision of MC1R, MC4R or MC5R selective targeting anticipates a new generation of analogs with thematically dedicated profiles.

Frequently asked research questions on melanocortins

Why is Melanotan II a pan-agonist and PT-141 MC4R-preferential, even though both molecules share the same sequence?

MT-II is cyclized by a lactam bridge between Asp⁵ and Lys¹⁰ that imposes a rigid conformation compatible with all MC1R-MC5R binding sites. PT-141 is linear, with a free acid C-terminal end, generating conformational flexibility preferring certain receptors (MC4R, MC3R) over others (MC1R). Cyclization is therefore the key structural determinant of receptor selectivity.

Does Melanotan II really produce tanning without sun exposure?

MT-II induces MC1R-mediated melanogenesis independent of UV exposure. Clinically, observations report progressive skin darkening over several weeks of repeated administration. This pigmentation is not equivalent to photo-protection because induced melanogenesis does not necessarily achieve the optimal eumelanin/pheomelanin ratio for full UVB protection. Photo-protective significance remains an active research topic.

How does PT-141 mechanistically differ from PDE5 inhibitors (sildenafil, tadalafil)?

PDE5 inhibitors act peripherally on corpus cavernosum by blocking cyclic GMP degradation, amplifying nitric oxide-dependent vasodilation. PT-141 acts centrally on MC4R neurons of the paraventricular nucleus and preoptic area, triggering the motivational and erectile cascade via neural projections. The two mechanisms are independent and complementary.

Why is afamelanotide marketed as a subcutaneous implant rather than an injection?

Scenesse is formulated as a biodegradable 16 mg implant releasing afamelanotide over 60 days. This format enables sustained pharmacological exposure suited to summer photo-protection in EPP patients, without imposing repeated injections. The commercial decision also rests on afamelanotide's chemical stability in polylactide-coglycolide matrix, ensuring near-linear release.